Cargando…

Plasma and cerebrospinal fluid nonenzymatic protein damage is sustained in Alzheimer's disease

BACKGROUND: Oxidative stress is considered to play an important role in the pathogenesis of Alzheimer's disease (AD). It has been observed that oxidative damage to specific protein targets affecting particular functional networks is one of the mechanisms by which oxidative stress contributes to...

Descripción completa

Detalles Bibliográficos
Autores principales: Dakterzada, Farida, Jové, Mariona, Cantero, José Luís, Pamplona, Reinald, Piñoll-Ripoll, Gerard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300255/
https://www.ncbi.nlm.nih.gov/pubmed/37339560
http://dx.doi.org/10.1016/j.redox.2023.102772
_version_ 1785064546895921152
author Dakterzada, Farida
Jové, Mariona
Cantero, José Luís
Pamplona, Reinald
Piñoll-Ripoll, Gerard
author_facet Dakterzada, Farida
Jové, Mariona
Cantero, José Luís
Pamplona, Reinald
Piñoll-Ripoll, Gerard
author_sort Dakterzada, Farida
collection PubMed
description BACKGROUND: Oxidative stress is considered to play an important role in the pathogenesis of Alzheimer's disease (AD). It has been observed that oxidative damage to specific protein targets affecting particular functional networks is one of the mechanisms by which oxidative stress contributes to neuronal failure and consequently loss of cognition and AD progression. Studies are lacking in which oxidative damage is measured at both systemic and central fluid levels and in the same cohort of patients. We aimed to determine the levels of both plasma and cerebrospinal fluid (CSF) nonenzymatic protein damage in patients in the continuum of AD and to evaluate the relation of this damage with clinical progression from mild cognitive impairment (MCI) to AD. METHODS: Different markers of nonenzymatic post-translational protein modification, mostly from oxidative processes, were detected and quantified in plasma and CSF by isotope dilution gas chromatography‒mass spectrometry using selected ion monitoring (SIM-GC/MS) for 289 subjects: 103 AD, 92 MCI, and 94 control subjects. Characteristics of the study population such as age, sex, Mini-mental state examination, CSF AD biomarkers, and APOE ϵ4, were also considered. RESULTS: Forty-seven (52.8%) MCI patients progressed to AD during follow-up (58 ± 12.5 months). After controlling for age, sex, and APOE ϵ4 allele, plasma and CSF concentrations of protein damage markers were not associated with either diagnosis of AD or MCI. The CSF levels of nonenzymatic protein damage markers were associated with none of the CSF AD biomarkers. In addition, neither in CSF nor in plasma were the levels of protein damage associated with the MCI to AD progression. CONCLUSION: The lack of association between both CSF and plasma concentrations of nonenzymatic protein damage markers and AD diagnosis and progression suggests that oxidative damage in AD is a pathogenic mechanism specifically expressed at the cell-tissue level, not in extracellular fluids.
format Online
Article
Text
id pubmed-10300255
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-103002552023-06-29 Plasma and cerebrospinal fluid nonenzymatic protein damage is sustained in Alzheimer's disease Dakterzada, Farida Jové, Mariona Cantero, José Luís Pamplona, Reinald Piñoll-Ripoll, Gerard Redox Biol Research Paper BACKGROUND: Oxidative stress is considered to play an important role in the pathogenesis of Alzheimer's disease (AD). It has been observed that oxidative damage to specific protein targets affecting particular functional networks is one of the mechanisms by which oxidative stress contributes to neuronal failure and consequently loss of cognition and AD progression. Studies are lacking in which oxidative damage is measured at both systemic and central fluid levels and in the same cohort of patients. We aimed to determine the levels of both plasma and cerebrospinal fluid (CSF) nonenzymatic protein damage in patients in the continuum of AD and to evaluate the relation of this damage with clinical progression from mild cognitive impairment (MCI) to AD. METHODS: Different markers of nonenzymatic post-translational protein modification, mostly from oxidative processes, were detected and quantified in plasma and CSF by isotope dilution gas chromatography‒mass spectrometry using selected ion monitoring (SIM-GC/MS) for 289 subjects: 103 AD, 92 MCI, and 94 control subjects. Characteristics of the study population such as age, sex, Mini-mental state examination, CSF AD biomarkers, and APOE ϵ4, were also considered. RESULTS: Forty-seven (52.8%) MCI patients progressed to AD during follow-up (58 ± 12.5 months). After controlling for age, sex, and APOE ϵ4 allele, plasma and CSF concentrations of protein damage markers were not associated with either diagnosis of AD or MCI. The CSF levels of nonenzymatic protein damage markers were associated with none of the CSF AD biomarkers. In addition, neither in CSF nor in plasma were the levels of protein damage associated with the MCI to AD progression. CONCLUSION: The lack of association between both CSF and plasma concentrations of nonenzymatic protein damage markers and AD diagnosis and progression suggests that oxidative damage in AD is a pathogenic mechanism specifically expressed at the cell-tissue level, not in extracellular fluids. Elsevier 2023-06-04 /pmc/articles/PMC10300255/ /pubmed/37339560 http://dx.doi.org/10.1016/j.redox.2023.102772 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Paper
Dakterzada, Farida
Jové, Mariona
Cantero, José Luís
Pamplona, Reinald
Piñoll-Ripoll, Gerard
Plasma and cerebrospinal fluid nonenzymatic protein damage is sustained in Alzheimer's disease
title Plasma and cerebrospinal fluid nonenzymatic protein damage is sustained in Alzheimer's disease
title_full Plasma and cerebrospinal fluid nonenzymatic protein damage is sustained in Alzheimer's disease
title_fullStr Plasma and cerebrospinal fluid nonenzymatic protein damage is sustained in Alzheimer's disease
title_full_unstemmed Plasma and cerebrospinal fluid nonenzymatic protein damage is sustained in Alzheimer's disease
title_short Plasma and cerebrospinal fluid nonenzymatic protein damage is sustained in Alzheimer's disease
title_sort plasma and cerebrospinal fluid nonenzymatic protein damage is sustained in alzheimer's disease
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300255/
https://www.ncbi.nlm.nih.gov/pubmed/37339560
http://dx.doi.org/10.1016/j.redox.2023.102772
work_keys_str_mv AT dakterzadafarida plasmaandcerebrospinalfluidnonenzymaticproteindamageissustainedinalzheimersdisease
AT jovemariona plasmaandcerebrospinalfluidnonenzymaticproteindamageissustainedinalzheimersdisease
AT canterojoseluis plasmaandcerebrospinalfluidnonenzymaticproteindamageissustainedinalzheimersdisease
AT pamplonareinald plasmaandcerebrospinalfluidnonenzymaticproteindamageissustainedinalzheimersdisease
AT pinollripollgerard plasmaandcerebrospinalfluidnonenzymaticproteindamageissustainedinalzheimersdisease